• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

    80.32 -5.52 (-6.43%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,726,788
    Open 85.53
    Bid (Size) 81.05 (100)
    Ask (Size) 90.00 (1,100)
    Prev. Close 85.84
    Today's Range 80.21 - 85.53
    52wk Range 13.37 - 88.02
    Shares Outstanding 60,648,883
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
    Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal... 
    Via Finterra
    Topics Economy

    Performance

    YTD
    +102.4%
    +102.4%
    1 Month
    +52.4%
    +52.4%
    3 Month
    +84.3%
    +84.3%
    6 Month
    +111.9%
    +111.9%
    1 Year
    +243.5%
    +243.5%

    More News

    Read More
    News headline image
    Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
    Via Stocktwits
    Gapping stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy
    News headline image
    Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Participate in Four Investor Conferences During November
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗
    Via Benzinga
    News headline image
    3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗
    Via Benzinga
    News headline image
    Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
    Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
    The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
    What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
    The current price of Dianthus Therapeutics, Inc. - Common Stock is 80.32
    When was Dianthus Therapeutics, Inc. - Common Stock last traded?
    The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 03/12/26 04:00 PM ET
    What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?
    The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 4.87B
    How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?
    Dianthus Therapeutics, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.